B
MRTX

Braidwell’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Braidwell’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-240,625
Closed -$8.69M – 96
2023
Q2 		$8.69M Sell
240,625
-211,375
-47% -$8.71M 0.28% 73
2023
Q1 		$16.8M Buy
452,000
+38,400
+9% +$1.73M 0.55% 57
2022
Q4 		$18.7M Buy
+413,600
New +$26.8M 0.63% 54

Other funds holding MRTX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Braidwell's MRTX Position: Q3 2023 in Review

Braidwell sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 240,625 shares — an estimated $8.69M sold.

Braidwell first reported a position in MRTX in Q4 2022 and held it in 3 quarters. The position peaked at $18.7M in Q4 2022. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

  • Braidwell reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Braidwell sold 240,625 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $8.69M.
  • Braidwell first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • Braidwell's Mirati Therapeutics, Inc. Common Stock position peaked at $18.7M in Q4 2022.
  • 213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Braidwell's 13F filing for Q3 2023, filed 14 Nov 2023.